Relief Therapeutics Announces Positive Results from Pivotal Bioequivalence Study of RLF-OD032

AI SummaryClose X

Relief Therapeutics announced positive results from its pivotal bioequivalence study of RLF-OD032, a liquid formulation of sapropterin dihydrochloride, for treating phenylketonuria (PKU). The study demonstrated that RLF-OD032 is bioequivalent to KUVAN Powder, meeting the primary pharmacokinetic endpoints as defined by the U.S. Food and Drug Administration. RLF-OD032 was well-tolerated, with no serious adverse events reported. The company plans to submit a 505(b)(2) New Drug Application (NDA) in early 2026, seeking U.S. marketing approval, which will be subject to a 10-month FDA review. RLF-OD032 offers up to a 100-fold reduction in dose volume compared to current formulations.

Disclaimer*

UK 100

Latest directors dealings